SCHEMBL6628341

SCHEMBL6628341

COc1cc([N+](=O)[O-])cc2c1OC1(C=C2)N(C)c2ccc(N3C(=O)CCC3=O)cc2C1(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.44
KMT2A Q03164 5/20 0.44
GFER P55789 1/20 0.44
MAPT P10636 8/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
GAA P10253 3/20 0.35
MAPK1 P28482 2/20 0.35
LMNA P02545 3/20 0.34
NPSR1 Q6W5P4 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
ALPG P10696 1/20 0.34
RECQL P46063 1/20 0.34
TP53 P04637 1/20 0.34
ALOX15 P16050 1/20 0.34
HSD17B10 Q99714 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.33
POLB P06746 3/20 0.32
APEX1 P27695 1/20 0.32
CASP6 P55212 1/20 0.32
CTDSP1 Q9GZU7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6628087 0.88 MEN1 (0.36) MEN1KMT2AGFERMAPTSMN1; SMN2
SCHEMBL11788015 0.86 KMT2A (0.57) MEN1KMT2AGFERMAPTSMN1; SMN2
SCHEMBL30612721 0.86 KMT2A (0.57) MEN1KMT2AGFERMAPTSMN1; SMN2
SCHEMBL6628094 0.86 MAPT (0.39) MEN1KMT2AGFERMAPTSMN1; SMN2
SCHEMBL8680217 0.85 MEN1 (0.48) MEN1KMT2AGFERMAPTSMN1; SMN2
SCHEMBL8680176 0.85 KMT2A (0.48) MEN1KMT2AGFERMAPTSMN1; SMN2
SCHEMBL8680196 0.84 KMT2A (0.48) MEN1KMT2AGFERMAPTSMN1; SMN2
SCHEMBL30612733 0.84 MEN1 (0.48) MEN1KMT2AGFERMAPTSMN1; SMN2
SCHEMBL6140171 0.84 MEN1 (0.48) MEN1KMT2AGFERMAPTSMN1; SMN2
SCHEMBL6139989 0.84 MEN1 (0.48) MEN1KMT2AGFERMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1299391-B1 INDOLINOSPIROPYRAN COMPOUNDS AND METHODS FOR THEIR MANUFACTURE JOHNSON & JOHNSON VISION CARE (US) 2004-12-29 EP disclosed
US-6803471-B2 USEFUL AS PHOTOCHROMIC COMPOUNDS; COVALENTLY ATTACHED TO WANG RESINS AND METHOD OF ATTACHING; OPHTHALMIC LENSES JOHNSON & JOHNSON VISION CARE, INC. 2004-10-12 US disclosed
US-6521753-B1 Indolinospiropyran compounds and methods for their manufacture JOHNSON & JOHNSON VISION CARE, INC. 2003-02-18 US disclosed
US-20020087010-A1 Indolinospiropyran compounds and methods for their manufacture ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) 2002-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020087010-A1 Indolinospiropyran compounds and methods for their manufacture DHPS, IDO1, INMT MEN1 3140/4885KMT2A 2464/4885GFER 1614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.